Keryx Biopharmaceuticals — Investor Presentation (December 2014)
26 slides from Keryx Biopharmaceuticals's investor presentation, Dec 11, 2014

Slide 1: Keryx Biopharmaceuticals Corporate Presentation December 2014
Exhibit 99.1 At Keryx, when Tenth Biopharmaceuticals, patient Floorthe New care patient York, improves, Inc. comes NY| 10022 first. everybody Our Boston, goal succeeds. MA is to02210 bring NEW innovative 1.212.531.5965 YORK BOSTON therapies tel 1.Keryx to617.466.3500 market Biopharmaceuticals, that

Slide 2: Safe Harbor Statement
Safe Litigation Riona® concur successful Securities 1Q update by Keryx 2014 Harbor these with will Form Biopharmaceuticals, and Reform inour Statement be forward-looking the Exchange 10-Q, successfully interpretation development Actasof Various well Commission. 1995. marketed as statements of Inc. r

Slide 3: FDA Approved: Auryxia (ferric citrate)
FDA For by chronic the the Approved: Company?s control kidney of disease AuryxiaTM serum Japanese Geographical phosphorus partner, (ferric citrate) Japan levels expansion: Tobacco Approved in patients EUInc. and on with and emerging September chronic Torii Pharmaceutical markets kidney 5, 2014, dise

Slide 4: Chronic Kidney Disease in the U.S.
Chronic WITH http://www.kidney.org/kidneydisease; National year. Copyright CKD Kidney Institute 16 2014 MILLION Disease of Diabetes by Keryx in WITH theand U.S. Biopharmaceuticals, Digestive 450,000 WeU.S. believe ON Renal andDIALYSIS that Kidney Data the Inc. System, CKD Diseases, | 3STAGE patient

Slide 5: Typical Disease Burden of Dialysis Patients
Typical Disease Elevated Vitamin Iron Erythropoietin Receive dialysis ESAs, All regularly Copyright parameters) parameters deficient vitamin Dialysis session Burden D multiple phosphorous (including 2014 deficient Take deficient D, monitored (including Treatment by Patients IV antibiotics, Keryx mul

Slide 6: Dialysis Providers and Bundled Payment System
Dialysis Responsible D, etc. Oral Providers drugs for clinical (e.g. U.S.phosphate Top care15 andU.S. operations binders) providers are Bundled not oversee included payment care of in the ~90% system bundle ofDialysis dialysis until 2024 providers patients Injectable Davita, receive drugs Fresenius,

Slide 7: Primary and Secondary Efficacy Endpoints
Primary Efficacy Baseline End p<0.0001 Secondary Change AuryxiaTM TSAT Serum Hemoglobin Reduction Control Active Copyright of+8% Phosphorous Ferritin Control Efficacy from Endpoint Assessment Serum 2014 in Endpoints -1% Active (ferric Placebo -0.2 ESA IV Baseline +302 -52% Phosphorous by Period Iron

Slide 8: The First and Only Absorbable Iron-Based Phosphate Binder
The First and AuryxiaTM reduction in has dose Only been orAbsorbable-Iron-Based discontinuation shown to increase of IV serum iron. Phosphate iron Copyright parameters, Binder 2014 Indication: including by Keryxthe ferritin, Biopharmaceuticals, controliron of and serum TSAT. phosphorus Inc.Mean | 7

Slide 9: Auryxia Differentiation from Non-Calcium Binders
AuryxiaTM entrant iron 895 remained (482) parameters, into relatively ng/mL, the (ferric phosphate including mean citrate) constant. (SD) binder ferritin, Differentiation Copyright TSAT market iron levels and 2014 with Drug rose TSAT. by the from Phosphate Keryx additional In31% dialysis Biopharmace

Slide 10: Preparing for Launch
Preparing for Launch NEW YORK | BOSTON | WWW.KERYX.COM Copyright 2014 by Keryx Biopharmaceuticals, Inc. | 9

Slide 11: Hyperphosphatemia Market Overview
Hyperphosphatemia millions) $1,200 $1,400 in $(S Annual 2009 $0 $200 ?Fosrenol ales AuryxiaTM $8002010 $600 $400 Phoslo/Phoslyra/Calcium $1,000 2011 is only 2012Market iron-based 2013 Overview phosphate Acetate – U.S. binder Renegel/Renvela/Sevelamer ? Five that phosphate is absorbed binders Copyrig

Slide 12: Historic Phosphate Binder Launch Analogs
Historic 30,000 Renagel Phoslo 35,000 TRxs Velphoro Calendarized Aligned -M 5,000 Time —10,000 Source: 1 M225,000 Fosrenol M3 IMS Analogs: 15,000 M4 NPA Phosphate 20,000 M524 Monthly M6 Month Binder M7Velphoro Launch M8TA_Average M9 Aligned M10 2nd & M11Uptake M12 3rdM13 Month M14areM15 projecte

Slide 13: Launch Analysis of Drug Launches Since 2006
Analysis 250,000 200,000 •5150,000 100,000 N=38 -2150,648 Mean 32% 21,966 0,000 006 Source: –cumulative 2008 N=56 166,956 of all 2009 IMSUSN=50 TRx NPA –Drug 2010 through All •Launches 2011 Launches first – 2012 Post 12from months 2006 2006ofthrough launch 2012. Excludes Trimmed products launches wi

Slide 14: Reimbursement and Payer Coverage
Reimbursement patients scheduledareformularies LIS Top Driven 15atpayers/PBMs by launch Part Dtoand takecover Commercial place95% by end eligible Plans of April Medicare of commercial Co-pay Part assistance D lives Commercial Top in 15 place Part Insurers toD3 plans PartMedicare Dcover formulary 95%

Slide 15: Market Approach
Market oApproach INFLUENCE Affairs Biopharmaceuticals, SalesPayer/Patient team Within oInc. Account |the 14Access phosphate Mgmt, Prescribers Medical binder market, Dialysis Affairs prescriber ?AuryxiaTM Organizations decision Value?AuryxiaTM ?Target?Target?Target making is influenced Value?AuryxiaT

Slide 16: Dialysis Population in the United States
Dialysis in Population Follow-up) Disease Prevalence the (427,340 (102,029 Unitedand patients) patients) States Turnover 152011 GAIN Every Incident 26%year ofDialysis patients approximately Population TURNOVER 25%(112,788 ofLOSS the ESRD patients) 25% population of patients 2010 Point turns Source:

Slide 17: Auryxia Business Opportunity and Patient Sources
AuryxiaTM benefits (hypercalcemia, clinical properties Current Coretolerability, Dynamics/ Sources Copyright ofOpportunity efficacy) Business 2014 by Keryx Opportunity—capture Sources ~45%Biopharmaceuticals, of start Business on sevelamer, New reactive Patient Inc. ~40% switches | 16 Starts on calci

Slide 18: Critical Success Factors
CriticalCopyright KOL’s Success Factors 2014 byYear Keryx 1 Drive Biopharmaceuticals, brand awareness Inc. Establish | 17 unique positioning and differentiation Create broad access through payers Ensure patient affordability through access programs Broaden our base of

Slide 19: Growth Opportunities
Growth Opportunities NEW YORK | BOSTON | WWW.KERYX.COM Copyright 2014 by Keryx Biopharmaceuticals, Inc. |

Slide 20: Chronic Kidney Disease in the U.S.
ChronicCKD WITH http://www.kidney.org/kidneydisease; National CopyrightKidney Institute 2014 450,000 by Disease ofKeryx Diabetes ONinDIALYSIS Biopharmaceuticals, theand U.S. Digestive We ~80% U.S. believe Renal ON andInc. that PHOSPHATE Kidney Data |the 19System, CKD Diseases, patient BINDERS USRDS

Slide 21: Anemia in Pre-Dialysis CKD Patients
Anemiaisconstraints liability anemia and leftPre-Dialysis untreated Currently AnCKD oral available Patients iron formulation oral Welliron overpreparations that 1.5ismillion absorbed do CKDnot could stages work be in a3-5 welcome most patients dialysis addition havepatients iron to deficiency theand

Slide 22: Potential Indication Expansion: NDD-CKD Iron Deficiency Anemia
Potential in with Placebo Baseline Phosphorus TSAT Ferritin Hemoglobin Intact Clinicaltrials.gov NDD-CKD a FGF-23 (%) washout (ng/mL) (n=69) EOT Indication 21(mg/dL) (g/dL) 20 Baseline patients (pg/mL) from Ferric 110 22 identifier: 10.6 Expansion: 32 both 4.7 106 Citrate (Stage <0.001 263 EOT 4.4 1

Slide 23: Iron Deficiency Anemia Phase 3 Trial
Iron Deficiency hemoglobin identifier: NCT02268994 at any Anemia point Phase during Copyright 3the Trial 16-week 2014 Study byInitiated randomization Keryx Biopharmaceuticals, in September period 2-month 2014 ~230 Inc.safety | stage 22 follow 3 5 CKD up period, patients forwith a total ironofdeficie

Slide 24: International Expansion
International is Biopharmaceuticals, currently ~$350M Expansion Inc. andOn growing | 23January EU17, marketing 2014, ourauthorization Japanese partner, application JT/Torii, is under received review; marketing decision approval expected in Japan mid-2015 for Ferric Determining Citrate (Riona) best p

Slide 25: FDA Approved and Growth Areas
FDA Approved: kidney dependent disease chronic (CKD) AuryxiaTM kidney on dialysis disease (ferricFirst Geographical citrate) and Approved only expansion: absorbed on September iron-based EU and emerging 5,phosphate 2014, by markets binder the U.S. Copyright U.S. Food launch and2014 Drug at YE byAdmi

Slide 26: Keryx contact information
At Keryx, when 1.212.531.5965 Keryx patient Biopharmaceuticals, thecare patient telimproves, 1.212.531.5961 comesInc. first. everybody Our faxgoal www.keryx.com succeeds. is to bring Corporate innovative BOSTON Presentation therapies Keryx NASDAQ: Biopharmaceuticals, to market that KERX provide | De
Source: SEC EDGAR · 8-K filed Dec 11, 2014
More decks from Keryx Biopharmaceuticals Inc
Merger or Acquisition (November 2018)19 slides · Nov 16, 2018
Q2 2018 Earnings Presentation17 slides · Aug 8, 2018
Q1 2018 Earnings Presentation19 slides · May 10, 2018
FY2017 Earnings Presentation23 slides · Feb 7, 2018
Q3 2017 Earnings Presentation28 slides · Nov 7, 2017
Q2 2017 Earnings Presentation16 slides · Jul 27, 2017